Molecular targeted therapy: A new avenue in glioblastoma treatment (Review)

Hanif F, Muzaffar K, Perveen K, Malhi SM and Simjee SHU: Glioblastoma multiforme: A review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 18:3–9. 2017.PubMed/NCBI

Karachi A, Dastmalchi F, Mitchell DA and Rahman M: Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol. 20:1566–1572. 2018. View Article : Google Scholar : PubMed/NCBI

Delgado-López PD and Corrales-García EM: Survival in glioblastoma: A review on the impact of treatment modalities. Clin Transl Oncol. 18:1062–1071. 2016. View Article : Google Scholar : PubMed/NCBI

Tamimi AF and Juweid M: Epidemiology and outcome of glioblastoma. Glioblastoma. De Vleeschouwer S: Codon Publications; Brisbane, AU: 2017, Available from:. http://www.ncbi.nlm.nih.gov/books/NBK470003/ View Article : Google Scholar

Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI

Hubbard SR: Structural analysis of receptor tyrosine kinases. Prog Biophys Mol Biol. 71:343–358. 1999. View Article : Google Scholar : PubMed/NCBI

Montor WR, Salas AROSE and Melo FHM: Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: The current arsenal of inhibitors. Mol Cancer. 17:552018. View Article : Google Scholar : PubMed/NCBI

Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature. 411:355–365. 2001. View Article : Google Scholar : PubMed/NCBI

Hunter T: Tyrosine phosphorylation: Thirty years and counting. Curr Opin Cell Biol. 21:140–146. 2009. View Article : Google Scholar : PubMed/NCBI

Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, et al: The somatic genomic landscape of glioblastoma. Cell. 155:462–477. 2013. View Article : Google Scholar : PubMed/NCBI

Wen PY and Kesari S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2018. View Article : Google Scholar : PubMed/NCBI

Chakravarti A, Chakladar A, Delaney MA, Latham DE and Loeffler JS: The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary human glioblastoma cells in a RAS-dependent manner. Cancer Res. 62:4307–4315. 2002.PubMed/NCBI

Mazzoleni S, Politi LS, Pala M, Cominelli M, Franzin A, Sergi Sergi L, Falini A, De Palma M, Bulfone A, Poliani PL and Galli R: Epidermal growth factor receptor expression identifies functionally and molecularly distinct tumor-initiating cells in human glioblastoma multiforme and is required for gliomagenesis. Cancer Res. 70:7500–7513. 2010. View Article : Google Scholar : PubMed/NCBI

Li L, Dutra A, Pak E, Labrie JE III, Gerstein RM, Pandolfi PP, Recht LD and Ross AH: EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 11:9–21. 2009. View Article : Google Scholar : PubMed/NCBI

Hatanpaa KJ, Burma S, Zhao D and Habib AA: Epidermal growth factor receptor in glioma: Signal transduction, neuropathology, imaging, and radioresistance. Neoplasia. 12:675–684. 2010. View Article : Google Scholar : PubMed/NCBI

Talasila KM, Soentgerath A, Euskirchen P, Rosland GV, Wang J, Huszthy PC, Prestegarden L, Skaftnesmo KO, Sakariassen PØ, Eskilsson E, et al: EGFR wild-type amplification and activation promote invasion and development of glioblastoma independent of angiogenesis. Acta Neuropathol. 125:683–698. 2013. View Article : Google Scholar : PubMed/NCBI

Bonavia R, Inda MM, Vandenberg S, Cheng SY, Nagane M, Hadwiger P, Tan P, Sah DW, Cavenee WK and Furnari FB: EGFRvIII promotes glioma angiogenesis and growth through the NF-κB, interleukin-8 pathway. Oncogene. 31:4054–4066. 2012. View Article : Google Scholar : PubMed/NCBI

Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T and Koizumi F: Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. Mol Cancer. 12:312013. View Article : Google Scholar : PubMed/NCBI

Feng H, Hu B, Vuori K, Sarkaria JN, Furnari FB, Cavenee WK and Cheng SY: EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180. Oncogene. 33:2504–2512. 2014. View Article : Google Scholar : PubMed/NCBI

Eskilsson E, Rosland GV, Talasila KM, Knappskog S, Keunen O, Sottoriva A, Foerster S, Solecki G, Taxt T, Jirik R, et al: EGFRvIII mutations can emerge as late and heterogenous events in glioblastoma development and promote angiogenesis through Src activation. Neuro Oncol. 18:1644–1655. 2016. View Article : Google Scholar : PubMed/NCBI

Roos A, Dhruv HD, Peng S, Inge LJ, Tuncali S, Pineda M, Millard N, Mayo Z, Eschbacher JM, Loftus JC, et al: EGFRvIII-Stat5 signaling enhances glioblastoma cell migration and survival. Mol Cancer Res. 16:1185–1195. 2018. View Article : Google Scholar : PubMed/NCBI

Sugawa N, Ekstrand AJ, James CD and Collins VP: Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci USA. 87:8602–8606. 1990. View Article : Google Scholar : PubMed/NCBI

Frederick L, Wang XY, Eley G and James CD: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res. 60:1383–1387. 2000.PubMed/NCBI

Cruz Da Silva E, Mercier MC, Etienne-Selloum N, Dontenwill M and Choulier L: A systematic review of glioblastoma-targeted therapies in phases II, III, IV clinical trials. Cancers (Basel). 13:17952021. View Article : Google Scholar : PubMed/NCBI

Van Den Bent M, Eoli M, Sepulveda JM, Smits M, Walenkamp A, Frenel JS, Franceschi E, Clement PM, Chinot O, De Vos F, et al: INTELLANCE 2/EORTC 1410 randomized Phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro Oncol. 22:684–693. 2020. View Article : Google Scholar : PubMed/NCBI

Solomon MT, Miranda N, Jorrín E, Chon I, Marinello JJ, Alert J, Lorenzo-Luaces P and Crombet T: Nimotuzumab in combination with radiotherapy in high grade glioma patients: A single institution experience. Cancer Biol Ther. 15:504–509. 2014. View Article : Google Scholar : PubMed/NCBI

Reardon DA, Nabors LB, Mason WP, Perry JR, Shapiro W, Kavan P, Mathieu D, Phuphanich S, Cseh A, Fu Y, et al: Phase I/randomized Phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro Oncol. 17:430–439. 2015.PubMed/NCBI

Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, et al: Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol. 13:324–333. 2011. View Article : Google Scholar : PubMed/NCBI

Paulsson J, Lindh MB, Jarvius M, Puputti M, Nistér M, Nupponen NN, Paulus W, Söderberg O, Dresemann G, von Deimling A, et al: Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma. Int J Cancer. 128:1981–1988. 2011. View Article : Google Scholar : PubMed/NCBI

Plate KH, Breier G, Farrell CL and Risau W: Platelet-derived growth factor receptor-beta is induced during tumor development and upregulated during tumor progression in endothelial cells in human gliomas. Lab Invest. 67:529–534. 1992.PubMed/NCBI

Camorani S, Esposito CL, Rienzo A, Catuogno S, Iaboni M, Condorelli G, de Franciscis V and Cerchia L: Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFRβ aptamer. Mol Ther. 22:828–841. 2014. View Article : Google Scholar : PubMed/NCBI

Vassbotn FS, Ostman A, Langeland N, Holmsen H, Westermark B, Heldin CH and Nistér M: Activated platelet-derived growth factor autocrine pathway drives the transformed phenotype of a human glioblastoma cell line. J Cell Physiol. 158:381–389. 1994. View Article : Google Scholar : PubMed/NCBI

Lokker NA, Sullivan CM, Hollenbach SJ, Israel MA and Giese NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: Evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. 62:3729–3735. 2002.PubMed/NCBI

Cattaneo MG, Gentilini D and Vicentini LM: Deregulated human glioma cell motility: Inhibitory effect of somatostatin. Mol Cell Endocrinol. 256:34–39. 2006. View Article : Google Scholar : PubMed/NCBI

Kwak Y, Kim SI, Park CK, Paek SH, Lee ST and Park SH: C-MET overexpression and amplification in gliomas. Int J Clin Exp Pathol. 8:14932–14938. 2015.PubMed/NCBI

Bender S, Gronych J, Warnatz HJ, Hutter B, Gröbner S, Ryzhova M, Pfaff E, Hovestadt V, Weinberg F, Halbach S, et al: Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. Nat Med. 22:1314–1320. 2016. View Article : Google Scholar : PubMed/NCBI

Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, et al: A Phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 13:437–446. 2011. View Article : Google Scholar : PubMed/NCBI

Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, et al: c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci USA. 108:9951–9956. 2011. View Article : Google Scholar : PubMed/NCBI

Jahangiri A, De Lay M, Miller LM, Carbonell WS, Hu YL, Lu K, Tom MW, Paquette J, Tokuyasu TA, Tsao S, et al: Gene expression profile identifies tyrosine kinase c-Met as a targetable mediator of antiangiogenic therapy resistance. Clin Cancer Res. 19:1773–1783. 2013. View Article : Google Scholar : PubMed/NCBI

Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF and Xie Q: Genomic profiling of a hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. J Transl Med. 13:3062015. View Article : Google Scholar : PubMed/NCBI

Cruickshanks N, Zhang Y, Yuan F, Pahuski M, Gibert M and Abounader R: Role and therapeutic targeting of the HGF/MET pathway in glioblastoma. Cancers (Basel). 9:872017. View Article : Google Scholar : PubMed/NCBI

Yang K, Wu Z, Zhang H, Zhang N, Wu W, Wang Z, Dai Z, Zhang X, Zhang L, Peng Y, et al: Glioma targeted therapy: Insight into future of molecular approaches. Mol Cancer. 21:392022. View Article : Google Scholar : PubMed/NCBI

Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, et al: Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 25:477–486. 2019. View Article : Google Scholar : PubMed/NCBI

Torre M, Vasudevaraja V, Serrano J, DeLorenzo M, Malinowski S, Blandin AF, Pages M, Ligon AH, Dong F, Meredith DM, et al: Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 8:1072020. View Article : Google Scholar : PubMed/NCBI

Jimenez-Pascual A, Mitchell K, Siebzehnrubl FA and Lathia JD: FGF2: A novel druggable target for glioblastoma? Expert Opin Ther Targets. 24:311–318. 2020. View Article : Google Scholar : PubMed/NCBI

Feldkamp MM, Lau N and Guha A: The farnesyltransferase inhibitor L-744,832 inhibits the growth of astrocytomas through a combination of antiproliferative, antiangiogenic, and proapoptotic activities. Ann N Y Acad Sci. 886:257–260. 1999. View Article : Google Scholar : PubMed/NCBI

Kowalewski A, Durślewicz J, Zdrenka M, Grzanka D and Szylberg Ł: Clinical relevance of BRAF V600E mutation status in brain tumors with a focus on a novel management algorithm. Target Oncol. 15:531–540. 2020. View Article : Google Scholar : PubMed/NCBI

Dischinger PS, Tovar EA, Essenburg CJ, Madaj ZB, Gardner EE, Callaghan ME, Turner AN, Challa AK, Kempston T, Eagleson B, et al: NF1 deficiency correlates with estrogen receptor signaling and diminished survival in breast cancer. NPJ Breast Cancer. 4:292018. View Article : Google Scholar : PubMed/NCBI

Arima Y, Hayashi H, Kamata K, Goto TM, Sasaki M, Kuramochi A and Saya H: Decreased expression of neurofibromin contributes to epithelial-mesenchymal transition in neurofibromatosis type 1. Exp Dermatol. 19:e136–e141. 2010. View Article : Google Scholar : PubMed/NCBI

Altwairgi AK, Alghareeb WA, AlNajjar FH, Alhussain H, Alsaeed E, Balbaid AAO, Aldanan S, Orz Y and Alsharm AA: Atorvastatin in combination with radiotherapy and temozolomide for glioblastoma: A prospective Phase II study. Invest New Drugs. 39:226–231. 2021. View Article : Google Scholar : PubMed/NCBI

Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–519. 2006. View Article : Google Scholar : PubMed/NCBI

Mondin VE, Ben El Kadhi K, Cauvin C, Jackson-Crawford A, Bélanger E, Decelle B, Salomon R, Lowe M, Echard A and Carréno S: PTEN reduces endosomal PtdIns(4,5)P₂ in a phosphatase-independent manner via a PLC pathway. J Cell Biol. 218:2198–2214. 2019. View Article : Google Scholar : PubMed/NCBI

Han F, Hu R, Yang H, Liu J, Sui J, Xiang X, Wang F, Chu L and Song S: PTEN gene mutations correlate to poor prognosis in glioma patients: A meta-analysis. Onco Targets Ther. 9:3485–3492. 2016.PubMed/NCBI

Chen C, Zhu S, Zhang X, Zhou T, Gu J, Xu Y, Wan Q, Qi X, Chai Y, Liu X, et al: Targeting the synthetic vulnerability of PTEN-deficient glioblastoma cells with MCL1 inhibitors. Mol Cancer Ther. 19:2001–2011. 2020. View Article : Google Scholar : PubMed/NCBI

Zhao JJ, Liu Z, Wang L, Shin E, Loda MF and Roberts TM: The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci USA. 102:18443–18448. 2005. View Article : Google Scholar : PubMed/NCBI

Thorpe LM, Yuzugullu H and Zhao JJ: PI3K in cancer: Divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 15:7–24. 2015. View Article : Google Scholar : PubMed/NCBI

McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI

Parsons DW, Jones S, Zhang X, Lin JCH, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, et al: An integrated genomic analysis of human glioblastoma multiforme. Science. 321:1807–1812. 2008. View Article : Google Scholar : PubMed/NCBI

Weber GL, Parat MO, Binder ZA, Gallia GL and Riggins GJ: Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2:833–849. 2011. View Article : Google Scholar : PubMed/NCBI

Quayle SN, Lee JY, Cheung LWT, Ding L, Wiedemeyer R, Dewan RW, Huang-Hobbs E, Zhuang L, Wilson RK, Ligon KL, et al: Somatic mutations of PIK3R1 promote gliomagenesis. PLoS One. 7:e494662012. View Article : Google Scholar : PubMed/NCBI

Gallia GL, Rand V, Siu IM, Eberhart CG, James CD, Marie SKN, Oba-Shinjo SM, Carlotti CG, Caballero OL, Simpson AJ, et al: PIK3CA gene mutations in pediatric and adult glioblastoma multiforme. Mol Cancer Res. 4:709–714. 2006. View Article : Google Scholar : PubMed/NCBI

Tanaka S, Batchelor TT, Iafrate AJ, Dias-Santagata D, Borger DR, Ellisen LW, Yang D, Louis DN, Cahill DP and Chi AS: PIK3CA activating mutations are associated with more disseminated disease at presentation and earlier recurrence in glioblastoma. Acta Neuropathol Commun. 7:662019. View Article : Google Scholar : PubMed/NCBI

England B, Huang T and Karsy M: Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumour Biol. 34:2063–2074. 2013. View Article : Google Scholar : PubMed/NCBI

Ohgaki H: Genetic pathways to glioblastomas. Neuropathology. 25:1–7. 2005. View Article : Google Scholar : PubMed/NCBI

Olafson LR, Gunawardena M, Nixdorf S, McDonald KL and Rapkin RW: The role of TP53 gain-of-function mutation in multifocal glioblastoma. J Neurooncol. 147:37–47. 2020. View Article : Google Scholar : PubMed/NCBI

Fontemaggi G, Dell'Orso S, Trisciuoglio D, Shay T, Melucci E, Fazi F, Terrenato I, Mottolese M, Muti P, Domany E, et al: The execution of the transcriptional axis mutant p53, E2F1 and ID4 promotes tumor neo-angiogenesis. Nat Struct Mol Biol. 16:1086–1093. 2009. View Article : Google Scholar : PubMed/NCBI

Ham SW, Jeon HY, Jin X, Kim EJ, Kim JK, Shin YJ, Lee Y, Kim SH, Lee SY, Seo S, et al: TP53 gain-of-function mutation promotes inflammation in glioblastoma. Cell Death Differ. 26:409–425. 2019. View Article : Google Scholar : PubMed/NCBI

Pedrote MM, Motta MF, Ferretti GDS, Norberto DR, Spohr TCLS, Lima FRS, Gratton E, Silva JL and de Oliveira GAP: Oncogenic gain of function in glioblastoma is linked to mutant p53 amyloid oligomers. iScience. 23:1008202020. View Article : Google Scholar : PubMed/NCBI

Tao W and Levine AJ: P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. Proc Natl Acad Sci USA. 96:6937–6941. 1999. View Article : Google Scholar : PubMed/NCBI

Nakamura M, Watanabe T, Klangby U, Asker C, Wiman K, Yonekawa Y, Kleihues P and Ohgaki H: p14ARF deletion and methylation in genetic pathways to glioblastomas. Brain Pathol. 11:159–168. 2001. View Article : Google Scholar : PubMed/NCBI

Reifenberger G, Liu L, Ichimura K, Schmidt EE and Collins VP: Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:2736–2739. 1993.PubMed/NCBI

Riemenschneider MJ, Büschges R, Wolter M, Reifenberger J, Boström J, Kraus JA, Schlegel U and Reifenberger G: Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification1. Cancer Res. 59:6091–6096. 1999.PubMed/NCBI

Xiong Y, Zhang Y, Xiong S and Williams-Villalobo AE: A glance of p53 functions in brain development, neural stem cells, and brain cancer. Biology (Basel). 9:2852020.PubMed/NCBI

Sherr CJ and McCormick F: The RB and p53 pathways in cancer. Cancer Cell. 2:103–112. 2002. View Article : Google Scholar : PubMed/NCBI

Allen BK, Stathias V, Maloof ME, Vidovic D, Winterbottom EF, Capobianco AJ, Clarke J, Schurer S, Robbins DJ and Ayad NG: Epigenetic pathways and glioblastoma treatment: Insights from signaling cascades. J Cell Biochem. 116:351–363. 2015. View Article : Google Scholar : PubMed/NCBI

Romani M, Pistillo MP and Banelli B: Epigenetic targeting of glioblastoma. Front Oncol. 8:4482018. View Article : Google Scholar : PubMed/NCBI

Roos WP, Batista LFZ, Naumann SC, Wick W, Weller M, Menck CFM and Kaina B: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene. 26:186–197. 2007. View Article : Google Scholar : PubMed/NCBI

Yu W, Zhang L, Wei Q and Shao A: O6-methylguanine-DNA methyltransferase (MGMT): Challenges and new opportunities in glioma chemotherapy. Front Oncol. 9:15472020. View Article : Google Scholar : PubMed/NCBI

Zhang J, Chen L, Han L, Shi Z, Zhang J, Pu P and Kang C: EZH2 is a negative prognostic factor and exhibits pro-oncogenic activity in glioblastoma. Cancer Lett. 356:929–936. 2015. View Article : Google Scholar : PubMed/NCBI

Sharma V, Malgulwar PB, Purkait S, Patil V, Pathak P, Agrawal R, Kulshreshtha R, Mallick S, Julka PK, Suri A, et al: Genome-wide ChIP-seq analysis of EZH2-mediated H3K27me3 target gene profile highlights differences between low- and high-grade astrocytic tumors. Carcinogenesis. 38:152–161. 2017.PubMed/NCBI

Mohammad F, Weissmann S, Leblanc B, Pandey DP, Højfeldt JW, Comet I, Zheng C, Johansen JV, Rapin N, Porse BT, et al: EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nat Med. 23:483–492. 2017. View Article : Google Scholar : PubMed/NCBI

Lee DH, Kim GW, Yoo J, Lee SW, Jeon YH, Kim SY, Kang HG, Kim DH, Chun KH, Choi J and Kwon SH: Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc. Cell Death Dis. 12:892021. View Article : Google Scholar : PubMed/NCBI

Ceccacci E and Minucci S: Inhibition of histone deacetylases in cancer therapy: Lessons from leukaemia. Br J Cancer. 114:605–611. 2016. View Article : Google Scholar : PubMed/NCBI

Lee P, Murphy B, Miller R, Menon V, Banik NL, Giglio P, Lindhorst SM, Varma AK, Vandergrift WA III, Patel SJ and Das A: Mechanisms and clinical significance of histone deacetylase inhibitors: Epigenetic glioblastoma therapy. Anticancer Res. 35:615–625. 2015.PubMed/NCBI

Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y and Wang Y: The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res. 39:1382020. View Article : Google Scholar : PubMed/NCBI

Harbour JW, Luo RX, Santi AD, Postigo AA and Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell. 98:859–869. 1999. View Article : Google Scholar : PubMed/NCBI

Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF and Sherr CJ: Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 71:323–334. 1992. View Article : Google Scholar : PubMed/NCBI

Cooper S and Shayman JA: Revisiting retinoblastoma protein phosphorylation during the mammalian cell cycle. Cell Mol Life Sci. 58:580–595. 2001. View Article : Google Scholar : PubMed/NCBI

Taylor JW, Parikh M, Phillips JJ, James CD, Molinaro AM, Butowski NA, Clarke JL, Oberheim-Bush NA, Chang SM, Berger MS and Prados M: Phase-2 trial of palbociclib in adult patients with recurrent RB1-positive glioblastoma. J Neurooncol. 140:477–483. 2018. View Article : Google Scholar : PubMed/NCBI

Goldberg AL: Protein degradation and protection against misfolded or damaged proteins. Nature. 426:895–899. 2003. View Article : Google Scholar : PubMed/NCBI

Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr and Chen ZS: Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 48:1006632020. View Article : Google Scholar : PubMed/NCBI

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, et al: Phase 2 study of bortezomib combined with temozolomide and regional radiation therapy for upfront treatment of patients with newly diagnosed glioblastoma multiforme: safety and efficacy assessment. Int J Radiat Oncol Biol Phys. 100:1195–1203. 2018. View Article : Google Scholar : PubMed/NCBI

Di K, Lloyd GK, Abraham V, MacLaren A, Burrows FJ, Desjardins A, Trikha M and Bota DA: Marizomib activity as a single agent in malignant gliomas: Ability to cross the blood-brain barrier. Neuro Oncol. 18:840–848. 2016. View Article : Google Scholar : PubMed/NCBI

Roth P, Mason WP, Richardson PG and Weller M: Proteasome inhibition for the treatment of glioblastoma. Expert Opin Investig Drugs. 29:1133–1141. 2020. View Article : Google Scholar : PubMed/NCBI

Quillin J, Patel R, Herzberg E, Alton D, Bikzhanova G, Geisler L and Olson J: A phase 0 analysis of ixazomib in patients with glioblastoma. Mol Clin Oncol. 13:432020. View Article : Google Scholar : PubMed/NCBI

Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, DeWees TA, Lockhart AC and Kim AH: Final results of a Phase I dose-escalation, dose-expansion study of adding disulfiram with or without copper to adjuvant temozolomide for newly diagnosed glioblastoma. J Neurooncol. 138:105–111. 2018. View Article : Google Scholar : PubMed/NCBI

Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, Chinnaiyan P, Wan L, Marcus S and Campian JL: A multicenter Phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma. J Neurooncol. 142:537–544. 2019. View Article : Google Scholar : PubMed/NCBI

Carruthers R and Chalmers AJ: Improving the therapeutic ratio of radiotherapy by targeting the DNA damage response. Increasing the Therapeutic Ratio of Radiotherapy. Series: Cancer Drug Discovery and Development. Tofilon PJ and Camphausen K: Humana Press; Cham: pp. 1–34. 2017, View Article : Google Scholar

Murnyák B, Kouhsari MC, Hershkovitch R, Kálmán B, Marko-Varga G, Klekner Á and Hortobágyi T: PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma. Oncotarget. 8:46348–46362. 2017. View Article : Google Scholar : PubMed/NCBI

Chalmers AJ: Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents Med Chem. 10:520–533. 2010. View Article : Google Scholar : PubMed/NCBI

Hanna C, Kurian KM, Williams K, Watts C, Jackson A, Carruthers R, Strathdee K, Cruickshank G, Dunn L, Erridge S, et al: Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: Results of the Phase I OPARATIC trial. Neuro Oncol. 22:1840–1850. 2020. View Article : Google Scholar : PubMed/NCBI

Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, et al: A randomized Phase I/II study of ABT-888 in combination with temozoflomide in recurrent temozolomide resistant glioblastoma: An NRG oncology RTOG group study. J Neurooncol. 126:309–316. 2016. View Article : Google Scholar : PubMed/NCBI

Baxter PA, Su JM, Onar-Thomas A, Billups CA, Li XN, Poussaint TY, Smith ER, Thompson P, Adesina A, Ansell P, et al: A Phase I/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: A pediatric brain tumor consortium study. Neuro Oncol. 22:875–885. 2020. View Article : Google Scholar : PubMed/NCBI

Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organi-zation classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI

Jo SH, Son MK, Koh HJ, Lee SM, Song IH, Kim YO, Lee YS, Jeong KS, Kim WB, Park JW, et al: Control of mitochondrial redox balance and cellular defense against oxidative damage by mitochondrial NADP+-dependent isocitrate dehydrogenase. J Biol Chem. 276:16168–16176. 2001. View Article : Google Scholar : PubMed/NCBI

Lee SM, Koh HJ, Park DC, Song BJ, Huh TL and Park JW: Cytosolic NADP(+)-dependent isocitrate dehydrogenase status modulates oxidative damage to cells. Free Radic Biol Med. 32:1185–1196. 2002. View Article : Google Scholar : PubMed/NCBI

Kim SY and Park JW: Cellular defense against singlet oxygen-induced oxidative damage by cytosolic NADP+-dependent isocitrate dehydrogenase. Free Radic Res. 37:309–316. 2003. View Article : Google Scholar : PubMed/NCBI

Krell D, Assoku M, Galloway M, Mulholland P, Tomlinson I and Bardella C: Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma. PLoS One. 6:e198682011. View Article : Google Scholar : PubMed/NCBI

Arita H, Narita Y, Yoshida A, Hashimoto N, Yoshimine T and Ichimura K: IDH1/2 mutation detection in gliomas. Brain Tumor Pathol. 32:79–89. 2015. View Article : Google Scholar : PubMed/NCBI

Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, et al: IDH1 and IDH2 mutations in gliomas. N Engl J Med. 360:765–773. 2009. View Article : Google Scholar : PubMed/NCBI

Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, Ackermann U, Tessmer C, Korshunov A, Zentgraf H, et al: Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20:245–254. 2010. View Article : Google Scholar : PubMed/NCBI

Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, et al: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 462:739–744. 2009. View Article : Google Scholar : PubMed/NCBI

Xu W, Yang H, Liu Y, Yang Y, Wang P, Kim SH, Ito S, Yang C, Wang P, Xiao MT, et al: Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell. 19:17–30. 2011. View Article : Google Scholar : PubMed/NCBI

Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, et al: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 483:474–478. 2012. View Article : Google Scholar : PubMed/NCBI

Yalaza C, Ak H, Cagli MS, Ozgiray E, Atay S and Aydin HH: R132H mutation in IDH1 gene is associated with increased tumor HIF1-alpha and serum VEGF levels in primary glioblastoma multiforme. Ann Clin Lab Sci. 47:362–364. 2017.PubMed/NCBI

Flavahan WA, Drier Y, Liau BB, Gillespie SM, Venteicher AS, Stemmer-Rachamimov AO, Suvà ML and Bernstein BE: Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature. 529:110–114. 2016. View Article : Google Scholar : PubMed/NCBI

Fu Y, Zheng S, Zheng Y, Huang R, An N, Liang A and Hu C: Glioma derived isocitrate dehydrogenase-2 mutations induced up-regulation of HIF-1α and β-catenin signaling: Possible impact on glioma cell metastasis and chemo-resistance. Int J Biochem Cell Biol. 44:770–775. 2012. View Article : Google Scholar : PubMed/NCBI

Warburg O: On respiratory impairment in cancer cells. Science. 124:269–270. 1956. View Article : Google Scholar : PubMed/NCBI

Stern R, Shuster S, Neudecker BA and Formby B: Lactate stimulates fibroblast expression of hyaluronan and CD44: The Warburg effect revisited. Exp Cell Res. 276:24–31. 2002. View Article : Google Scholar : PubMed/NCBI

Kroemer G and Pouyssegur J: Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell. 13:472–482. 2008. View Article : Google Scholar : PubMed/NCBI

Vander Heiden MG, Cantley LC and Thompson CB: Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI

Saier MH Jr: Families of transmembrane sugar transport proteins. Mol Microbiol. 35:699–710. 2000. View Article : Google Scholar : PubMed/NCBI

Scheepers A, Joost H and Schürmann A: The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr. 28:364–371. 2004. View Article : Google Scholar : PubMed/NCBI

Flavahan WA, Wu Q, Hitomi M, Rahim N, Kim Y, Sloan AE, Weil RJ, Nakano I, Sarkaria JN, Stringer BW, et al: Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat Neurosci. 16:1373–1382. 2013. View Article : Google Scholar : PubMed/NCBI

Libby CJ, Gc S, Benavides GA, Fisher JL, Williford SE, Zhang S, Tran AN, Gordon ER, Jones AB, Tuy K, et al: A role for GLUT3 in glioblastoma cell invasion that is not recapitulated by GLUT1. Cell Adh Migr. 15:101–115. 2021. View Article : Google Scholar : PubMed/NCBI

Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C and Guha A: Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 208:313–326. 2011. View Article : Google Scholar : PubMed/NCBI

Vartanian A, Agnihotri S, Wilson MR, Burrell KE, Tonge PD, Alamsahebpour A, Jalali S, Taccone MS, Mansouri S, Golbourn B, et al: Targeting hexokinase 2 enhances response to radio-chemotherapy in glioblastoma. Oncotarget. 7:69518–69535. 2016. View Article : Google Scholar : PubMed/NCBI

Pastorino JG, Shulga N and Hoek JB: Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J Biol Chem. 277:7610–7618. 2002. View Article : Google Scholar : PubMed/NCBI

Agnihotri S, Mansouri S, Burrell K, Li M, Mamatjan Y, Liu J, Nejad R, Kumar S, Jalali S, Singh SK, et al: Ketoconazole and posaconazole selectively target HK2-expressing glioblastoma cells. Clin Cancer Res. 25:844–855. 2019. View Article : Google Scholar : PubMed/NCBI

Harada K, Saheki S, Wada K and Tanaka T: Purification of four pyruvate kinase isozymes of rats by affinity elution chromatography. Biochim Biophys Acta. 524:327–339. 1978. View Article : Google Scholar : PubMed/NCBI

Verma H, Cholia RP, Kaur S, Dhiman M and Mantha AK: A short review on cross-link between pyruvate kinase (PKM2) and glioblastoma multiforme. Metab Brain Dis. 36:751–765. 2021. View Article : Google Scholar : PubMed/NCBI

Uyeda K: Pyruvate kinase. Encyclopedia of Biological Chemistry. (2nd edition). Lennarz WJ and Lane MD: Academic Press; Waltham: pp. 719–721. 2013, Available from:. https://www.sciencedirect.com/science/article/pii/B9780123786302000530 View Article : Google Scholar

Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM and Pieper RO: Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 8:e576102013. View Article : Google Scholar : PubMed/NCBI

Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, Aldape K, Hunter T, Alfred Yung WK and Lu Z: PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 150:685–696. 2012. View Article : Google Scholar : PubMed/NCBI

Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, Aldape K, Wei C, Guo F, Chen Y and Lu Z: PKM2 regulates chromosome segregation and mitosis progression of tumor cells. Mol Cell. 53:75–87. 2014. View Article : Google Scholar : PubMed/NCBI

Cholia RP, Dhiman M, Kumar R and Mantha AK: Oxidative stress stimulates invasive potential in rat C6 and human U-87 MG glioblastoma cells via activation and cross-talk between PKM2, ENPP2 and APE1 enzymes. Metab Brain Dis. 33:1307–1326. 2018. View Article : Google Scholar : PubMed/NCBI

Liang J, Cao R, Wang X, Zhang Y, Wang P, Gao H, Li C, Yang F, Zeng R, Wei P, et al: Mitochondrial PKM2 regulates oxidative stress-induced apoptosis by stabilizing Bcl2. Cell Res. 27:329–351. 2017. View Article : Google Scholar : PubMed/NCBI

Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, Aldape K and Lu Z: Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation. Nature. 480:118–122. 2011. View Article : Google Scholar : PubMed/NCBI

Chaneton B and Gottlieb E: Rocking cell metabolism: Revised functions of the key glycolytic regulator PKM2 in cancer. Trends Biochem Sci. 37:309–316. 2012. View Article : Google Scholar : PubMed/NCBI

Sizemore ST, Zhang M, Cho JH, Sizemore GM, Hurwitz B, Kaur B, Lehman NL, Ostrowski MC, Robe PA, Miao W, et al: Pyruvate kinase M2 regulates homologous recombination-mediated DNA double-strand break repair. Cell Res. 28:1090–1102. 2018. View Article : Google Scholar : PubMed/NCBI

Rieger J, Bähr O, Maurer GD, Hattingen E, Franz K, Brucker D, Walenta S, Kämmerer U, Coy JF, Weller M and Steinbach JP: ERGO: A pilot study of ketogenic diet in recurrent glioblastoma. Int J Oncol. 44:1843–1852. 2014. View Article : Google Scholar : PubMed/NCBI

Kucharzewska P, Christianson HC and Belting M: Global profiling of metabolic adaptation to hypoxic stress in human glioblastoma cells. PLoS One. 10:e01167402015. View Article : Google Scholar : PubMed/NCBI

Ogunrinu TA and Sontheimer H: Hypoxia increases the dependence of glioma cells on glutathione. J Biol Chem. 285:37716–37724. 2010. View Article : Google Scholar : PubMed/NCBI

Robertson DS: The physical chemistry of brain and neural cell membranes: An overview. Neurochem Res. 35:681–687. 2010. View Article : Google Scholar : PubMed/NCBI

Newsholme P, Lima MMR, Procopio J, Pithon-Curi TC, Doi SQ, Bazotte RB and Curi R: Glutamine and glutamate as vital metabolites. Braz J Med Biol Res. 36:153–163. 2003. View Article : Google Scholar : PubMed/NCBI

Bak LK, Schousboe A and Waagepetersen HS: The glutamate/GABA-glutamine cycle: Aspects of transport, neurotransmitter homeostasis and ammonia transfer. J Neurochem. 98:641–653. 2006. View Article : Google Scholar : PubMed/NCBI

Obara-Michlewska M and Szeliga M: Targeting glutamine addiction in gliomas. Cancers (Basel). 12:3102020. View Article : Google Scholar : PubMed/NCBI

Michalak KP, Maćkowska-Kędziora A, Sobolewski B and Woźniak P: Key roles of glutamine pathways in reprogramming the cancer metabolism. Oxid Med Cell Longev. 2015:9643212015. View Article : Google Scholar : PubMed/NCBI

Rubin H: Deprivation of glutamine in cell culture reveals its potential for treating cancer. Proc Natl Acad Sci USA. 116:6964–6968. 2019. View Article : Google Scholar : PubMed/NCBI

Ekici S, Nye JA, Neill SG, Allen JW, Shu HK and Fleischer CC: Glutamine imaging: A new avenue for glioma management. AJNR Am J Neuroradiol. 43:11–18. 2022. View Article : Google Scholar : PubMed/NCBI

de Groot JF, Liu TJ, Fuller G and Yung WKA: The excitatory amino acid transporter-2 induces apoptosis and decreases glioma growth in vitro and in vivo. Cancer Res. 65:1934–1940. 2005. View Article : Google Scholar : PubMed/NCBI

Lyons SA, Chung WJ, Weaver AK, Ogunrinu T and Sontheimer H: Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res. 67:9463–9471. 2007. View Article : Google Scholar : PubMed/NCBI

Dranoff G, Elion GB, Friedman HS and Bigner DD: Combination chemotherapy in vitro exploiting glutamine metabolism of human glioma and medulloblastoma. Cancer Res. 45:4082–4086. 1985.PubMed/NCBI

Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV, Tsukamoto T, Rojas CJ, Slusher BS, Rabinowitz JD, et al: Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 70:8981–8987. 2010. View Article : Google Scholar : PubMed/NCBI

Majewska E, Márquez J, Albrecht J and Szeliga M: Transfection with GLS2 glutaminase (GAB) sensitizes human glioblastoma cell lines to oxidative stress by a common mechanism involving suppression of the PI3K/AKT pathway. Cancers (Basel). 11:1152019. View Article : Google Scholar : PubMed/NCBI

Szeliga M, Obara-Michlewska M, Matyja E, Łazarczyk M, Lobo C, Hilgier W, Alonso FJ, Márquez J and Albrecht J: Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G glioma cells. Glia. 57:1014–1023. 2009. View Article : Google Scholar : PubMed/NCBI

Szeliga M, Zgrzywa A, Obara-Michlewska M and Albrecht J: Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. J Neurochem. 123:428–436. 2012. View Article : Google Scholar : PubMed/NCBI

Yin Y, Sun W, Xiang J, Deng L, Zhang B, Xie P, Qiao W, Zou J and Liu C: Glutamine synthetase functions as a negative growth regulator in glioma. J Neurooncol. 114:59–69. 2013. View Article : Google Scholar : PubMed/NCBI

Ye ZC, Rothstein JD and Sontheimer H: Compromised glutamate transport in human glioma cells: Reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J Neurosci. 19:10767–10777. 1999. View Article : Google Scholar : PubMed/NCBI

Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY and Sontheimer H: Inhibition of cystine uptake disrupts the growth of primary brain tumors. J Neurosci. 25:7101–7110. 2005. View Article : Google Scholar : PubMed/NCBI

Robe PA, Martin DH, Nguyen-Khac MT, Artesi M, Deprez M, Albert A, Vanbelle S, Califice S, Bredel M and Bours V: Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults. BMC Cancer. 9:3722009. View Article : Google Scholar : PubMed/NCBI

Sleire L, Skeie BS, Netland IA, Førde HE, Dodoo E, Selheim F, Leiss L, Heggdal JI, Pedersen PH, Wang J and Enger PØ: Drug repurposing: Sulfasalazine sensitizes gliomas to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene. 34:5951–5959. 2015. View Article : Google Scholar : PubMed/NCBI

Choi YK and Park KG: Targeting glutamine metabolism for cancer treatment. Biomol Ther (Seoul). 26:19–28. 2018. View Article : Google Scholar : PubMed/NCBI

Morris SM Jr: Enzymes of arginine metabolism. J Nutr. 134 (Suppl 10):2743S–2747S. 2765S–2767S. 2004. View Article : Google Scholar : PubMed/NCBI

Kuo MT, Savaraj N and Feun LG: Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 1:246–251. 2010. View Article : Google Scholar : PubMed/NCBI

Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE and Abi-Habib RJ: Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. J Neurooncol. 122:75–85. 2015. View Article : Google Scholar : PubMed/NCBI

Choy CT, Wong CH and Loong HHF: Low expressions of ASS1 and OTC in glioblastoma suggest the potential clinical use of recombinant human arginase (rhArg). J Neurooncol. 129:579–581. 2016. View Article : Google Scholar : PubMed/NCBI

Bobak Y, Kurlishchuk Y, Vynnytska-Myronovska B, Grydzuk O, Shuvayeva G, Redowicz MJ, Kunz-Schughart LA and Stasyk O: Arginine deprivation induces endoplasmic reticulum stress in human solid cancer cells. Int J Biochem Cell Biol. 70:29–38. 2016. View Article : Google Scholar : PubMed/NCBI

Pavlyk I, Rzhepetskyy Y, Jagielski AK, Drozak J, Wasik A, Pereverzieva G, Olchowik M, Kunz-Schugart LA, Stasyk O and Redowicz MJ: Arginine deprivation affects glioblastoma cell adhesion, invasiveness and actin cytoskeleton organization by impairment of β-actin arginylation. Amino Acids. 47:199–212. 2015. View Article : Google Scholar : PubMed/NCBI

Stasyk OV, Boretsky YR, Gonchar MV and Sibirny AA: Recombinant arginine-degrading enzymes in metabolic anticancer therapy and bioanalytics. Cell Biol Int. 39:246–252. 2015. View Article : Google Scholar : PubMed/NCBI

Stone EM, Chantranupong L and Georgiou G: The second-shell metal ligands of human arginase affect coordination of the nucleophile and substrate. Biochemistry. 49:10582–10588. 2010. View Article : Google Scholar : PubMed/NCBI

Al-Koussa H, Al-Haddad M, Abi-Habib R and El-Sibai M: Human recombinant arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits colorectal cancer cell migration and invasion. Int J Mol Sci. 20:60182019. View Article : Google Scholar : PubMed/NCBI

Khalil N and Abi-Habib RJ: [HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells. Invest New Drugs. 38:1236–1246. 2020. View Article : Google Scholar : PubMed/NCBI

Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE and Abi-Habib RJ: Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res. 37:1565–1571. 2013. View Article : Google Scholar : PubMed/NCBI

Nasreddine G, El-Sibai M and Abi-Habib RJ: Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian cancer cells is autophagy dependent. Invest New Drugs. 38:10–19. 2020. View Article : Google Scholar : PubMed/NCBI

Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN and Curley SA: Bioengineered human arginase I with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 4:138–146. 2011. View Article : Google Scholar : PubMed/NCBI

Yoon CY, Sung DJ, Lee JH, Kim AR, Oh CW, Je JH, Weon BM, Seol SK, Pyun A, Hwu Y, et al: Imaging of renal and prostate carcinoma with refractive index radiology. Int J Urol. 14:96–103. 2007. View Article : Google Scholar : PubMed/NCBI

Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PNM and Hsueh CT: Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol Oncol. 5:172012. View Article : Google Scholar : PubMed/NCBI

Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z, Wang Z, Sun Y, Wang S, Song P, et al: Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis. 5:e15632014. View Article : Google Scholar : PubMed/NCBI

Hou X, Chen S, Zhang P, Guo D and Wang B: Targeted arginine metabolism therapy: A dilemma in glioma treatment. Front Oncol. 12:9388472022. View Article : Google Scholar : PubMed/NCBI

Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, et al: Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol. 126:267–276. 2013. View Article : Google Scholar : PubMed/NCBI

Nonoguchi N, Ohta T, Oh JE, Kim YH, Kleihues P and Ohgaki H: TERT promoter mutations in primary and secondary glioblastomas. Acta Neuropathol. 126:931–937. 2013. View Article : Google Scholar : PubMed/NCBI

Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA Jr, Friedman AH, Friedman H, Gallia GL, Giovanella BC, et al: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA. 110:6021–6066. 2013. View Article : Google Scholar : PubMed/NCBI

Arita H, Yamasaki K, Matsushita Y, Nakamura T, Shimokawa A, Takami H, Tanaka S, Mukasa A, Shirahata M, Shimizu S, et al: A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas. Acta Neuropathol Commun. 4:792016. View Article : Google Scholar : PubMed/NCBI

Kikuchi Z, Shibahara I, Yamaki T, Yoshioka E, Shofuda T, Ohe R, Matsuda KI, Saito R, Kanamori M, Kanemura Y, et al: TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma. Neurooncol Adv. 2:vdaa1142020.PubMed/NCBI

Vuong HG, Nguyen TQ, Ngo TNM, Nguyen HC, Fung KM and Dunn IF: The interaction between TERT promoter mutation and MGMT promoter methylation on overall survival of glioma patients: A meta-analysis. BMC Cancer. 20:8972020. View Article : Google Scholar : PubMed/NCBI

Patel B, Taiwo R, Kim AH and Dunn GP: TERT, a promoter of CNS malignancies. Neurooncol Adv. 2:vdaa0252020.PubMed/NCBI

Picketts DJ, Higgs DR, Bachoo S, Blake DJ, Quarrell OW and Gibbons RJ: ATRX encodes a novel member of the SNF2 family of proteins: Mutations point to a common mechanism underlying the ATR-X syndrome. Hum Mol Genet. 5:1899–1907. 1996. View Article : Google Scholar : PubMed/NCBI

Jiao Y, Killela PJ, Reitman ZJ, Rasheed BA, Heaphy CM, de Wilde RF, Rodriguez FJ, Rosemberg S, Oba-Shinjo SM, Nagahashi Marie SK, et al: Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas. Oncotarget. 3:709–722. 2012. View Article : Google Scholar : PubMed/NCBI

Koschmann C, Calinescu AA, Nunez FJ, Mackay A, Fazal-Salom J, Thomas D, Mendez F, Kamran N, Dzaman M, Mulpuri L, et al: ATRX loss promotes tumor growth and impairs nonhomologous end joining DNA repair in glioma. Sci Transl Med. 8:328ra282016. View Article : Google Scholar : PubMed/NCBI

do Carmo A, Balça-Silva J, Matias D and Lopes MC: PKC signaling in glioblastoma. Cancer Biol Ther. 14:287–294. 2013. View Article : Google Scholar : PubMed/NCBI

Steinberg SF: Structural basis of protein kinase C isoform function. Physiol Rev. 88:1341–1378. 2008. View Article : Google Scholar : PubMed/NCBI

Leirdal M and Sioud M: Protein kinase Calpha isoform regulates the activation of the MAP kinase ERK1/2 in human glioma cells: Involvement in cell survival and gene expression. Mol Cell Biol Res Commun. 4:106–110. 2000. View Article : Google Scholar : PubMed/NCBI

Marquina-Sánchez B, González-Jorge J, Hansberg-Pastor V, Wegman-Ostrosky T, Baranda-Ávila N, Mejía-Pérez S, Camacho-Arroyo I and González-Arenas A: The interplay between intracellular progesterone receptor and PKC plays a key role in migration and invasion of human glioblastoma cells. J Steroid Biochem Mol Biol. 172:198–206. 2017. View Article : Google Scholar : PubMed/NCBI

Valdés-Rives SA, Arcos-Montoya D, de la Fuente-Granada M, Zamora-Sánchez CJ, Arias-Romero LE, Villamar-Cruz O, Camacho-Arroyo I, Pérez-Tapia SM and González-Arenas A: LPA1 receptor promotes progesterone receptor phosphorylation through PKCα in human glioblastoma cells. Cells. 10:8072021. View Article : Google Scholar : PubMed/NCBI

Yoshiji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M and Fukui H: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res. 59:4413–4418. 1999.PubMed/NCBI

Liu Z, Wei Y, Zhang L, Yee PP, Johnson M, Zhang X, Gulley M, Atkinson JM, Trebak M, Wang HG and Li W: Induction of store-operated calcium entry (SOCE) suppresses glioblastoma growth by inhibiting the Hippo pathway transcriptional coactivators YAP/TAZ. Oncogene. 38:120–139. 2019. View Article : Google Scholar : PubMed/NCBI

Chen Z, Forman LW, Williams RM and Faller DV: Protein kinase C-δ inactivation inhibits the proliferation and survival of cancer stem cells in culture and in vivo. BMC Cancer. 14:902014. View Article : Google Scholar : PubMed/NCBI

Kim MJ, Kim RK, Yoon CH, An S, Hwang SG, Suh Y, Park MJ, Chung HY, Kim IG and Lee SJ: Importance of PKCδ signaling in fractionated-radiation-induced expansion of glioma-initiating cells and resistance to cancer treatment. J Cell Sci. 124:3084–3094. 2011. View Article : Google Scholar : PubMed/NCBI

Sarkar S and Yong VW: Reduction of protein kinase C delta attenuates tenascin-C stimulated glioma invasion in three-dimensional matrix. Carcinogenesis. 31:311–317. 2010. View Article : Google Scholar : PubMed/NCBI

Lu J, Xu Z, Duan H, Ji H, Zhen Z, Li B, Wang H, Tang H, Zhou J, Guo T, et al: Tumor-associated macrophage interleukin-β promotes glycerol-3-phosphate dehydrogenase activation, glycolysis and tumorigenesis in glioma cells. Cancer Sci. 111:1979–1990. 2020. View Article : Google Scholar : PubMed/NCBI

Sharif TR and Sharif M: Overexpression of protein kinase C epsilon in astroglial brain tumor derived cell lines and primary tumor samples. Int J Oncol. 15:237–243. 1999.PubMed/NCBI

Okhrimenko H, Lu W, Xiang C, Hamburger N, Kazimirsky G and Brodie C: Protein kinase C-epsilon regulates the apoptosis and survival of glioma cells. Cancer Res. 65:7301–7309. 2005. View Article : Google Scholar : PubMed/NCBI

Besson A, Davy A, Robbins SM and Yong VW: Differential activation of ERKs to focal adhesions by PKC epsilon is required for PMA-induced adhesion and migration of human glioma cells. Oncogene. 20:7398–7407. 2001. View Article : Google Scholar : PubMed/NCBI

Besson A, Wilson TL and Yong VW: The anchoring protein RACK1 links protein kinase cepsilon to integrin beta chains. Requirements for adhesion and motility. J Biol Chem. 277:22073–22084. 2002. View Article : Google Scholar : PubMed/NCBI

Aeder SE, Martin PM, Soh JW and Hussaini IM: PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways. Oncogene. 23:9062–9069. 2004. View Article : Google Scholar : PubMed/NCBI

Uht RM, Amos S, Martin PM, Riggan AE and Hussaini IM: The protein kinase C-eta isoform induces proliferation in glioblastoma cell lines through an ERK/Elk-1 pathway. Oncogene. 26:2885–2893. 2007. View Article : Google Scholar : PubMed/NCBI

Hussaini IM, Carpenter JE, Redpath GT, Sando JJ, Shaffrey ME and Vandenberg SR: Protein kinase C-eta regulates resistance to UV- and gamma-irradiation-induced apoptosis in glioblastoma cells by preventing caspase-9 activation. Neuro Oncol. 4:9–21. 2002. View Article : Google Scholar : PubMed/NCBI

Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P and Goidts V: Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. Int J Cancer. 139:1776–1787. 2016. View Article : Google Scholar : PubMed/NCBI

Guo H, Gu F, Li W, Zhang B, Niu R, Fu L, Zhang N and Ma Y: Reduction of protein kinase C zeta inhibits migration and invasion of human glioblastoma cells. J Neurochem. 109:203–213. 2009. View Article : Google Scholar : PubMed/NCBI

Baldwin RM, Parolin DA and Lorimer IA: Regulation of glioblastoma cell invasion by PKC iota and RhoB. Oncogene. 27:3587–3595. 2008. View Article : Google Scholar : PubMed/NCBI

Odia Y, Iwamoto FM, Moustakas A, Fraum TJ, Salgado CA, Li A, Kreisl TN, Sul J, Butman JA and Fine HA: A Phase II trial of enzastaurin (LY317615) in combination with bevacizumab in adults with recurrent malignant gliomas. J Neurooncol. 127:127–135. 2016. View Article : Google Scholar : PubMed/NCBI

Sevastre AS, Costachi A, Tataranu LG, Brandusa C, Artene SA, Stovicek O, Alexandru O, Danoiu S, Sfredel V and Dricu A: Glioblastoma pharmacotherapy: A multifaceted perspective of conventional and emerging treatments (review). Exp Ther Med. 22:14082021. View Article : Google Scholar : PubMed/NCBI

Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, Fouse SD, Yamamoto S, Ueda H, Tatsuno K, et al: Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science. 343:189–193. 2014. View Article : Google Scholar : PubMed/NCBI

Stieber D, Golebiewska A, Evers L, Lenkiewicz E, Brons NHC, Nicot N, Oudin A, Bougnaud S, Hertel F, Bjerkvig R, et al: Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol. 127:203–219. 2014. View Article : Google Scholar : PubMed/NCBI

Neftel C, Laffy J, Filbin MG, Hara T, Shore ME, Rahme GJ, Richman AR, Silverbush D, Shaw ML, Hebert CM, et al: An integrative model of cellular states, plasticity, and genetics for glioblastoma. Cell. 178:835–849.e21. 2019. View Article : Google Scholar : PubMed/NCBI

Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 28:511–515. 2010. View Article : Google Scholar : PubMed/NCBI

Lauko A, Lo A, Ahluwalia MS and Lathia JD: Cancer cell heterogeneity and plasticity in glioblastoma and brain tumors. Semin Cancer Biol. 82:162–175. 2022. View Article : Google Scholar : PubMed/NCBI

Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817. 2011. View Article : Google Scholar : PubMed/NCBI

Nobusawa S, Lachuer J, Wierinckx A, Kim YH, Huang J, Legras C, Kleihues P and Ohgaki H: Intratumoral patterns of genomic imbalance in glioblastomas. Brain Pathol. 20:936–944. 2010.PubMed/NCBI

Kumar A, Boyle EA, Tokita M, Mikheev AM, Sanger MC, Girard E, Silber JR, Gonzalez-Cuyar LF, Hiatt JB, Adey A, et al: Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes. Genome Biol. 15:5302014. View Article : Google Scholar : PubMed/NCBI

Bhaduri A, Di Lullo E, Jung D, Müller S, Crouch EE, Espinosa CS, Ozawa T, Alvarado B, Spatazza J, Cadwell CR, et al: Outer radial glia-like cancer stem cells contribute to heterogeneity of glioblastoma. Cell Stem Cell. 26:48–63.e6. 2020. View Article : Google Scholar : PubMed/NCBI

Pang B, Xu J, Hu J, Guo F, Wan L, Cheng M and Pang L: Single-cell RNA-seq reveals the invasive trajectory and molecular cascades underlying glioblastoma progression. Mol Oncol. 13:2588–2603. 2019. View Article : Google Scholar : PubMed/NCBI

Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, Thokala R, Sheikh S, Saxena D, Prokop S, et al: A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 180:188–204.e22. 2020. View Article : Google Scholar : PubMed/NCBI

Iwadate Y: Plasticity in glioma stem cell phenotype and its therapeutic implication. Neurol Med Chir (Tokyo). 58:61–70. 2018. View Article : Google Scholar : PubMed/NCBI

Koso H, Takeda H, Yew CCK, Ward JM, Nariai N, Ueno K, Nagasaki M, Watanabe S, Rust AG, Adams DJ, et al: Transposon mutagenesis identifies genes that transform neural stem cells into glioma-initiating cells. Proc Natl Acad Sci USA. 109:E2998–E3007. 2012. View Article : Google Scholar : PubMed/NCBI

Wang X, Prager BC, Wu Q, Kim LJY, Gimple RC, Shi Y, Yang K, Morton AR, Zhou W, Zhu Z, et al: Reciprocal signaling between glioblastoma stem cells and differentiated tumor cells promotes malignant progression. Cell Stem Cell. 22:514–528.e5. 2018. View Article : Google Scholar : PubMed/NCBI

Hsu JF, Chu SM, Liao CC, Wang CJ, Wang YS, Lai MY, Wang HC, Huang HR and Tsai MH: Nanotechnology and nanocarrier-based drug delivery as the potential therapeutic strategy for glioblastoma multiforme: An update. Cancers (Basel). 13:1952021. View Article : Google Scholar : PubMed/NCBI

Lathia JD, Heddleston JM, Venere M and Rich JN: Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell. 8:482–485. 2011. View Article : Google Scholar : PubMed/NCBI

Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL and Yu JS: Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene. 23:9392–9400. 2004. View Article : Google Scholar : PubMed/NCBI

Brescia P, Ortensi B, Fornasari L, Levi D, Broggi G and Pelicci G: CD133 is essential for glioblastoma stem cell maintenance. Stem Cells. 31:857–869. 2013. View Article : Google Scholar : PubMed/NCBI

Carlsson SK, Brothers SP and Wahlestedt C: Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 6:1359–1370. 2014. View Article : Google Scholar : PubMed/NCBI

Nusse R: Wnt signaling and stem cell control. Cell Res. 18:523–527. 2008. View Article : Google Scholar : PubMed/NCBI

Sareddy GR, Kesanakurti D, Kirti PB and Babu PP: Nonsteroidal anti-inflammatory drugs diclofenac and celecoxib attenuates Wnt/β-catenin/Tcf signaling pathway in human glioblastoma cells. Neurochem Res. 38:2313–2322. 2013. View Article : Google Scholar : PubMed/NCBI

Yu JB, Jiang H and Zhan RY: Aberrant Notch signaling in glioblastoma stem cells contributes to tumor recurrence and invasion. Mol Med Rep. 14:1263–1268. 2016. View Article : Google Scholar : PubMed/NCBI

Shih IM and Wang TL: Notch signaling, gamma-secretase inhibitors, and cancer therapy. Cancer Res. 67:1879–1882. 2007. View Article : Google Scholar : PubMed/NCBI

de la Iglesia N, Puram SV and Bonni A: STAT3 regulation of glioblastoma pathogenesis. Curr Mol Med. 9:580–590. 2009. View Article : Google Scholar : PubMed/NCBI

Porporato PE, Filigheddu N, Pedro JMBS, Kroemer G and Galluzzi L: Mitochondrial metabolism and cancer. Cell Res. 28:265–280. 2018. View Article : Google Scholar : PubMed/NCBI

Sighel D, Notarangelo M, Aibara S, Re A, Ricci G, Guida M, Soldano A, Adami V, Ambrosini C, Broso F, et al: Inhibition of mitochondrial translation suppresses glioblastoma stem cell growth. Cell Rep. 35:1090242021. View Article : Google Scholar : PubMed/NCBI

Mai TT, Hamaï A, Hienzsch A, Cañeque T, Müller S, Wicinski J, Cabaud O, Leroy C, David A, Acevedo V, et al: Salinomycin kills cancer stem cells by sequestering iron in lysosomes. Nat Chem. 9:1025–1033. 2017. View Article : Google Scholar : PubMed/NCBI

Sharifzad F, Ghavami S, Verdi J, Mardpour S, Mollapour Sisakht M, Azizi Z, Taghikhani A, Łos MJ, Fakharian E, Ebrahimi M and Hamidieh AA: Glioblastoma cancer stem cell biology: Potential theranostic targets. Drug Resist Updat. 42:35–45. 2019. View Article : Google Scholar : PubMed/NCBI

Saunders NR, Dreifuss JJ, Dziegielewska KM, Johansson PA, Habgood MD, Møllgård K and Bauer HC: The rights and wrongs of blood-brain barrier permeability studies: A walk through 100 years of history. Front Neurosci. 8:4042014. View Article : Google Scholar : PubMed/NCBI

Daneman R and Prat A: The blood-brain barrier. Cold Spring Harb Perspect Biol. 7:a0204122015. View Article : Google Scholar : PubMed/NCBI

Liebner S, Fischmann A, Rascher G, Duffner F, Grote EH, Kalbacher H and Wolburg H: Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol. 100:323–331. 2000. View Article : Google Scholar : PubMed/NCBI

Wolburg H, Wolburg-Buchholz K, Kraus J, Rascher-Eggstein G, Liebner S, Hamm S, Duffner F, Grote EH, Risau W and Engelhardt B: Localization of claudin-3 in tight junctions of the blood-brain barrier is selectively lost during experimental autoimmune encephalomyelitis and human glioblastoma multiforme. Acta Neuropathol. 105:586–592. 2003. View Article : Google Scholar : PubMed/NCBI

Ishihara H, Kubota H, Lindberg RLP, Leppert D, Gloor SM, Errede M, Virgintino D, Fontana A, Yonekawa Y and Frei K: Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins. J Neuropathol Exp Neurol. 67:435–448. 2008. View Article : Google Scholar : PubMed/NCBI

Rama AR, Alvarez PJ, Madeddu R and Aranega A: ABC transporters as differentiation markers in glioblastoma cells. Mol Biol Rep. 41:4847–4851. 2014. View Article : Google Scholar : PubMed/NCBI

Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, et al: Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer. Clin Cancer Res. 16:5664–5678. 2010. View Article : Google Scholar : PubMed/NCBI

Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, et al: Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 29:770–781. 2012. View Article : Google Scholar : PubMed/NCBI

Tiwary S, Morales JE, Kwiatkowski SC, Lang FF, Rao G and McCarty JH: Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Sci Rep. 8:82672018. View Article : Google Scholar : PubMed/NCBI

Elmeliegy MA, Carcaboso AM, Tagen M, Bai F and Stewart CF: Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation. Clin Cancer Res. 17:89–99. 2011. View Article : Google Scholar : PubMed/NCBI

de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JHM and van Tellingen O: Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs. 30:443–449. 2012. View Article : Google Scholar : PubMed/NCBI

Oberoi RK, Mittapalli RK and Elmquist WF: Pharmacokinetic assessment of efflux transport in sunitinib distribution to the brain. J Pharmacol Exp Ther. 347:755–764. 2013. View Article : Google Scholar : PubMed/NCBI

Lin F, de Gooijer MC, Roig EM, Buil LCM, Christner SM, Beumer JH, Würdinger T, Beijnen JH and van Tellingen O: ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. Clin Cancer Res. 20:2703–2713. 2014. View Article : Google Scholar : PubMed/NCBI

de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W and van Tellingen O: Improved brain penetration and antitumor efficacy of temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia. 20:710–720. 2018. View Article : Google Scholar : PubMed/NCBI

Choi YH and Yu AM: ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 20:793–807. 2014. View Article : Google Scholar : PubMed/NCBI

Tran S, DeGiovanni PJ, Piel B and Rai P: Cancer nanomedicine: A review of recent success in drug delivery. Clin Transl Med. 6:442017. View Article : Google Scholar : PubMed/NCBI

Sun T, Zhang YS, Pang B, Hyun DC, Yang M and Xia Y: Engineered nanoparticles for drug delivery in cancer therapy. Angew Chem Int Ed Engl. 53:12320–12364. 2014.PubMed/NCBI

Budama-Kilinc Y, Kecel-Gunduz S, Cakir-Koc R, Aslan B, Bicak B, Kokcu Y, Ozel AE and Akyuz S: Structural characterization and drug delivery system of natural growth-modulating peptide against glioblastoma cancer. Int J Pept Res Ther. 27:2015–2028. 2021. View Article : Google Scholar

Pasut G: Grand challenges in nano-based drug delivery. Front Med Technol. 1:12019. View Article : Google Scholar : PubMed/NCBI

Ambruosi A, Gelperina S, Khalansky A, Tanski S, Theisen A and Kreuter J: Influence of surfactants, polymer and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul. 23:582–592. 2006. View Article : Google Scholar : PubMed/NCBI

Caraway CA, Gaitsch H, Wicks EE, Kalluri A, Kunadi N and Tyler BM: Polymeric nanoparticles in brain cancer therapy: A review of current approaches. Polymers (Basel). 14:29632022. View Article : Google Scholar : PubMed/NCBI

Ramalho MJ, Sevin E, Gosselet F, Lima J, Coelho MAN, Loureiro JA and Pereira MC: Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm. 545:84–92. 2018. View Article : Google Scholar : PubMed/NCBI

Kuang Y, Jiang X, Zhang Y, Lu Y, Ma H, Guo Y, Zhang Y, An S, Li J, Liu L, et al: Dual functional peptide-driven nanoparticles for highly efficient glioma-targeting and drug codelivery. Mol Pharm. 13:1599–1607. 2016. View Article : Google Scholar : PubMed/NCBI

Mathew EN, Berry BC, Yang HW, Carroll RS and Johnson MD: Delivering therapeutics to glioblastoma: Overcoming biological constraints. Int J Mol Sci. 23:17112022. View Article : Google Scholar : PubMed/NCBI

Wei KC, Chu PC, Wang HYJ, Huang CY, Chen PY, Tsai HC, Lu YJ, Lee PY, Tseng IC, Feng LY, et al: Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: A preclinical study. PLoS One. 8:e589952013. View Article : Google Scholar : PubMed/NCBI

Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K and Hynynen K: Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer. 121:901–907. 2007. View Article : Google Scholar : PubMed/NCBI

Coluccia D, Figueiredo CA, Wu MY, Riemenschneider AN, Diaz R, Luck A, Smith C, Das S, Ackerley C, O'Reilly M, et al: Enhancing glioblastoma treatment using cisplatin-gold-nanoparticle conjugates and targeted delivery with magnetic resonance-guided focused ultrasound. Nanomedicine. 14:1137–1148. 2018. View Article : Google Scholar : PubMed/NCBI

Timbie KF, Mead BP and Price RJ: Drug and gene delivery across the blood-brain barrier with focused ultrasound. J Control Release. 219:61–75. 2015. View Article : Google Scholar : PubMed/NCBI

Burgess A, Shah K, Hough O and Hynynen K: Focused ultrasound-mediated drug delivery through the blood-brain barrier. Expert Rev Neurother. 15:477–491. 2015. View Article : Google Scholar : PubMed/NCBI

Dutta D, Heo I and Clevers H: Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 23:393–410. 2017. View Article : Google Scholar : PubMed/NCBI

Nishida N, Yano H, Nishida T, Kamura T and Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag. 2:213–219. 2006. View Article : Google Scholar : PubMed/NCBI

Hillen F and Griffioen AW: Tumour vascularization: Sprouting angiogenesis and beyond. Cancer Metastasis Rev. 26:489–502. 2007. View Article : Google Scholar : PubMed/NCBI

Joseph JV, Conroy S, Pavlov K, Sontakke P, Tomar T, Eggens-Meijer E, Balasubramaniyan V, Wagemakers M, den Dunnen WF and Kruyt FA: Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α-ZEB1 axis. Cancer Lett. 359:107–116. 2015. View Article : Google Scholar : PubMed/NCBI

Huang W, Ding X, Ye H, Wang J, Shao J and Huang T: Hypoxia enhances the migration and invasion of human glioblastoma U87 cells through PI3K/Akt/mTOR/HIF-1α pathway. Neuroreport. 29:1578–1585. 2018. View Article : Google Scholar : PubMed/NCBI

Chen JWE, Lumibao J, Blazek A, Gaskins HR and Harley B: Hypoxia activates enhanced invasive potential and endogenous hyaluronic acid production by glioblastoma cells. Biomater Sci. 6:854–862. 2018. View Article : Google Scholar : PubMed/NCBI

Rosa P, Catacuzzeno L, Sforna L, Mangino G, Carlomagno S, Mincione G, Petrozza V, Ragona G, Franciolini F and Calogero A: BK channels blockage inhibits hypoxia-induced migration and chemoresistance to cisplatin in human glioblastoma cells. J Cell Physiol. 233:6866–6877. 2018. View Article : Google Scholar : PubMed/NCBI

Velásquez C, Mansouri S, Gutiérrez O, Mamatjan Y, Mollinedo P, Karimi S, Singh O, Terán N, Martino J, Zadeh G and Fernández-Luna JL: Hypoxia can induce migration of glioblastoma cells through a methylation-dependent control of ODZ1 gene expression. Front Oncol. 9:10362019. View Article : Google Scholar : PubMed/NCBI

Huang S, Michalek JE, Reardon DA, Wen PY, Floyd JR, Fox PT, Clarke GD, Jerabek PA, Schmainda KM, Muzi M, et al: Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and 18F-FMISO PET. Sci Rep. 11:76322021. View Article : Google Scholar : PubMed/NCBI

Chédeville AL and Madureira PA: The role of hypoxia in glioblastoma radiotherapy resistance. Cancers (Basel). 13:5422021. View Article : Google Scholar : PubMed/NCBI

Zhou W, Ke SQ, Huang Z, Flavahan W, Fang X, Paul J, Wu L, Sloan AE, McLendon RE, Li X, et al: Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat Cell Biol. 17:170–182. 2015. View Article : Google Scholar : PubMed/NCBI

Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK, Gumin J, Henry V, Colman H, Priebe W, et al: Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 9:67–78. 2010. View Article : Google Scholar : PubMed/NCBI

Yang F, He Z, Duan H, Zhang D, Li J, Yang H, Dorsey JF, Zou W, Nabavizadeh SA, Bagley SJ, et al: Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40. Nat Commun. 12:34242021. View Article : Google Scholar : PubMed/NCBI

Banyer JL, Hamilton NH, Ramshaw IA and Ramsay AJ: Cytokines in innate and adaptive immunity. Rev Immunogenet. 2:359–373. 2000.PubMed/NCBI

Conlon KC, Miljkovic MD and Waldmann TA: Cytokines in the treatment of cancer. J Interferon Cytokine Res. 39:6–21. 2019. View Article : Google Scholar : PubMed/NCBI

Zhu VF, Yang J, Lebrun DG and Li M: Understanding the role of cytokines in glioblastoma multiforme pathogenesis. Cancer Lett. 316:139–150. 2012. View Article : Google Scholar : PubMed/NCBI

Wakabayashi T, Kayama T, Nishikawa R, Takahashi H, Hashimoto N, Takahashi J, Aoki T, Sugiyama K, Ogura M, Natsume A and Yoshida J: A multicenter Phase I trial of combination therapy with interferon-β and temozolomide for high-grade gliomas (INTEGRA study): The final report. J Neurooncol. 104:573–577. 2011. View Article : Google Scholar : PubMed/NCBI

Han MH, Kim JM, Cheong JH, Ryu JI, Won YD, Nam GH and Kim CH: Efficacy of cytokine-induced killer cell immunotherapy for patients with pathologically pure glioblastoma. Front Oncol. 12:8516282022. View Article : Google Scholar : PubMed/NCBI

Iwami K, Natsume A and Wakabayashi T: Cytokine therapy of gliomas. Prog Neurol Surg. 32:79–89. 2018. View Article : Google Scholar : PubMed/NCBI

Xu S, Tang L, Li X, Fan F and Liu Z: Immunotherapy for glioma: Current management and future application. Cancer Lett. 476:1–12. 2020. View Article : Google Scholar : PubMed/NCBI

Zhang Y and Zhang Z: The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI

de Mello RA, Veloso AF, Esrom Catarina P, Nadine S and Antoniou G: Potential role of immunotherapy in advanced non-small-cell lung cancer. Onco Targets Ther. 10:21–30. 2016. View Article : Google Scholar : PubMed/NCBI

Dine J, Gordon R, Shames Y, Kasler MK and Barton-Burke M: Immune checkpoint inhibitors: An innovation in immunotherapy for the treatment and management of patients with cancer. Asia Pac J Oncol Nurs. 4:127–135. 2017. View Article : Google Scholar : PubMed/NCBI

Mpakali A and Stratikos E: The role of antigen processing and presentation in cancer and the efficacy of immune checkpoint inhibitor immunotherapy. Cancers (Basel). 13:1342021. View Article : Google Scholar : PubMed/NCBI

Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, Behymer MM, Knipp GT, Yun Y, Veronesi MC, et al: Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc Natl Acad Sci USA. 118:e21075071182021. View Article : Google Scholar : PubMed/NCBI

Rosenberg SA, Restifo NP, Yang JC, Morgan RA and Dudley ME: Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer. 8:299–308. 2008. View Article : Google Scholar : PubMed/NCBI

Redeker A and Arens R: Improving adoptive T cell therapy: The particular role of T cell costimulation, cytokines, and post-transfer vaccination. Front Immunol. 7:3452016. View Article : Google Scholar : PubMed/NCBI

Chruściel E, Urban-Wójciuk Z, Arcimowicz Ł, Kurkowiak M, Kowalski J, Gliwiński M, Marjański T, Rzyman W, Biernat W, Dziadziuszko R, et al: Adoptive cell therapy-harnessing antigen-specific T cells to target solid tumours. Cancers (Basel). 12:6832020. View Article : Google Scholar : PubMed/NCBI

Staquicini FI, Smith TL, Tang FHF, Gelovani JG, Giordano RJ, Libutti SK, Sidman RL, Cavenee WK, Arap W and Pasqualini R: Targeted AAVP-based therapy in a mouse model of human glioblastoma: A comparison of cytotoxic versus suicide gene delivery strategies. Cancer Gene Ther. 27:301–310. 2020. View Article : Google Scholar : PubMed/NCBI

Vigneswaran K, Neill S and Hadjipanayis CG: Beyond the World Health Organization grading of infiltrating gliomas: Advances in the molecular genetics of glioma classification. Ann Transl Med. 3:952015.PubMed/NCBI

Goodwin CR, Rath P, Oyinlade O, Lopez H, Mughal S, Xia S, Xia S, Li Y, Kaur H, Zhou X, et al: Crizotinib and erlotinib inhibits growth of c-Met⁺/EGFRvIII⁺ primary human glioblastoma xenografts. Clin Neurol Neurosurg. 171:26–33. 2018. View Article : Google Scholar : PubMed/NCBI

Sestito S, Runfola M, Tonelli M, Chiellini G and Rapposelli S: New multitarget approaches in the War against glioblastoma: A mini-perspective. Front Pharmacol. 9:8742018. View Article : Google Scholar : PubMed/NCBI

Lang F, Liu Y, Chou FJ and Yang C: Genotoxic therapy and resistance mechanism in gliomas. Pharmacol Ther. 228:1079222021. View Article : Google Scholar : PubMed/NCBI

Lassman AB, Pugh SL, Gilbert MR, Aldape KD, Geinoz S, Beumer JH, Christner SM, Komaki R, DeAngelis LM, Gaur R, et al: Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). Neuro Oncol. 17:992–998. 2015. View Article : Google Scholar : PubMed/NCBI

Baratta MG: Glioblastoma is ‘hot’ for personalized vaccines. Nat Rev Cancer. 19:1292019. View Article : Google Scholar : PubMed/NCBI

Wiwatchaitawee K, Quarterman JC, Geary SM and Salem AK: Enhancement of therapies for glioblastoma (GBM) using nanoparticle-based delivery systems. AAPS PharmSciTech. 22:712021. View Article : Google Scholar : PubMed/NCBI

Pearson JRD, Cuzzubbo S, McArthur S, Durrant LG, Adhikaree J, Tinsley CJ, Pockley AG and McArdle SEB: Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol. 11:5821062020. View Article : Google Scholar : PubMed/NCBI

Burger MC, Zhang C, Harter PN, Romanski A, Strassheimer F, Senft C, Tonn T, Steinbach JP and Wels WS: CAR-engineered NK cells for the treatment of glioblastoma: Turning innate effectors into precision tools for cancer immunotherapy. Front Immunol. 10:26832019. View Article : Google Scholar : PubMed/NCBI

Granzin M, Wagner J, Köhl U, Cerwenka A, Huppert V and Ullrich E: Shaping of natural killer cell antitumor activity by ex vivo cultivation. Front Immunol. 8:4582017. View Article : Google Scholar : PubMed/NCBI

Yu MW and Quail DF: Immunotherapy for glioblastoma: Current progress and challenges. Front Immunol. 12:6763012021. View Article : Google Scholar : PubMed/NCBI

Dietrich J, Rao K, Pastorino S and Kesari S: Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol. 4:233–242. 2011. View Article : Google Scholar : PubMed/NCBI

Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Buczkowski KA, Richards WG, Gandhi L, Redig AJ, Rodig SJ, Asahina H, et al: Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 7:105012016. View Article : Google Scholar : PubMed/NCBI

Chan HY, Choi J, Jackson C and Lim M: Combination immunotherapy strategies for glioblastoma. J Neurooncol. 151:375–391. 2021. View Article : Google Scholar : PubMed/NCBI

Bausart M, Préat V and Malfanti A: Immunotherapy for glioblastoma: The promise of combination strategies. J Exp Clin Cancer Res. 41:352022. View Article : Google Scholar : PubMed/NCBI

Oh T, Sayegh ET, Fakurnejad S, Oyon D, Lamano JB, DiDomenico JD, Bloch O and Parsa AT: Vaccine therapies in malignant glioma. Curr Neurol Neurosci Rep. 15:5082015. View Article : Google Scholar : PubMed/NCBI

Hollingsworth RE and Jansen K: Turning the corner on therapeutic cancer vaccines. NPJ Vaccines. 4:72019. View Article : Google Scholar : PubMed/NCBI

Liu J, Fu M, Wang M, Wan D, Wei Y and Wei X: Cancer vaccines as promising immuno-therapeutics: Platforms and current progress. J Hematol Oncol. 15:282022. View Article : Google Scholar : PubMed/NCBI

Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, et al: Neoantigen vaccine generates intratumoral T cell responses in Phase Ib glioblastoma trial. Nature. 565:234–239. 2019. View Article : Google Scholar : PubMed/NCBI

Hilf N, Kuttruff-Coqui S, Frenzel K, Bukur V, Stevanović S, Gouttefangeas C, Platten M, Tabatabai G, Dutoit V, van der Burg SH, et al: Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature. 565:240–245. 2019. View Article : Google Scholar : PubMed/NCBI

Inc. AB, . AIVITA biomedical's phase 2 glioblastoma trial shows improved progression free survival. [cited 2022 Aug 5]. Available from:. https://www.prnewswire.com/news-releases/aivita-biomedicals-phase-2-glioblastoma-trial-shows-improved-progression-free-survival-301307757.html

Burkhardt JK, Riina H, Shin BJ, Christos P, Kesavabhotla K, Hofstetter CP, Tsiouris AJ and Boockvar JA: Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival. World Neurosurg. 77:130–134. 2012. View Article : Google Scholar : PubMed/NCBI

Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, et al: Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science. 344:1396–1401. 2014. View Article : Google Scholar : PubMed/NCBI

Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 32:42–56.e6. 2017. View Article : Google Scholar : PubMed/NCBI

Petroni G, Buqué A, Zitvogel L, Kroemer G and Galluzzi L: Immunomodulation by targeted anticancer agents. Cancer Cell. 39:310–345. 2021. View Article : Google Scholar : PubMed/NCBI

Song Y, Fu Y, Xie Q, Zhu B, Wang J and Zhang B: Anti-angiogenic agents in combination with immune checkpoint inhibitors: A promising strategy for cancer treatment. Front Immunol. 11:19562020. View Article : Google Scholar : PubMed/NCBI

Selek L, Seigneuret E, Nugue G, Wion D, Nissou MF, Salon C, Seurin MJ, Carozzo C, Ponce F, Roger T and Berger F: Imaging and histological characterization of a human brain xenograft in pig: The first induced glioma model in a large animal. J Neurosci Methods. 221:159–165. 2014. View Article : Google Scholar : PubMed/NCBI

Khoshnevis M, Carozzo C, Bonnefont-Rebeix C, Belluco S, Leveneur O, Chuzel T, Pillet-Michelland E, Dreyfus M, Roger T, Berger F and Ponce F: Development of induced glioblastoma by implantation of a human xenograft in Yucatan minipig as a large animal model. J Neurosci Methods. 282:61–68. 2017. View Article : Google Scholar : PubMed/NCBI

Tora MS, Texakalidis P, Neill S, Wetzel J, Rindler RS, Hardcastle N, Nagarajan PP, Krasnopeyev A, Roach C, James R, et al: Lentiviral vector induced modeling of high-grade spinal cord glioma in minipigs. Sci Rep. 10:52912020. View Article : Google Scholar : PubMed/NCBI

Khoshnevis M, Carozzo C, Brown R, Bardiès M, Bonnefont-Rebeix C, Belluco S, Nennig C, Marcon L, Tillement O, Gehan H, et al: Feasibility of intratumoral 165Holmium siloxane delivery to induced U87 glioblastoma in a large animal model, the Yucatan minipig. PLoS One. 15:e02347722020. View Article : Google Scholar : PubMed/NCBI

Hicks WH, Bird CE, Pernik MN, Haider AS, Dobariya A, Abdullah KG, Aoun SG, Bentley RT, Cohen-Gadol AA, Bachoo RM, et al: Large animal models of glioma: Current status and future prospects. Anticancer Res. 41:5343–5353. 2021. View Article : Google Scholar : PubMed/NCBI

Zhao CY, Cheng R, Yang Z and Tian ZM: Nanotechnology for cancer therapy based on chemotherapy. Molecules. 23:8262018. View Article : Google Scholar : PubMed/NCBI

Zaimy MA, Saffarzadeh N, Mohammadi A, Pourghadamyari H, Izadi P, Sarli A, Moghaddam LK, Paschepari SR, Azizi H, Torkamandi S and Tavakkoly-Bazzaz J: New methods in the diagnosis of cancer and gene therapy of cancer based on nanoparticles. Cancer Gene Ther. 24:233–243. 2017. View Article : Google Scholar : PubMed/NCBI

Geletneky K, Hajda J, Angelova AL, Leuchs B, Capper D, Bartsch AJ, Neumann JO, Schöning T, Hüsing J, Beelte B, et al: Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first Phase I/IIa glioblastoma trial. Mol Ther. 25:2620–2634. 2017. View Article : Google Scholar : PubMed/NCBI

Angelova AL, Barf M, Geletneky K, Unterberg A and Rommelaere J: Immunotherapeutic potential of oncolytic H-1 parvovirus: Hints of glioblastoma microenvironment conversion towards immunogenicity. Viruses. 9:3822017. View Article : Google Scholar : PubMed/NCBI

Suryawanshi YR and Schulze AJ: Oncolytic viruses for malignant glioma: On the verge of success? Viruses. 13:12942021. View Article : Google Scholar : PubMed/NCBI

Li J, Wang W, Wang J, Cao Y, Wang S and Zhao J: Viral gene therapy for glioblastoma multiforme: A promising hope for the current dilemma. Front Oncol. 11:6782262021. View Article : Google Scholar : PubMed/NCBI

Clement PMJ, Dirven L, Eoli M, Sepulveda-Sanchez JM, Walenkamp AME, Frenel JS, Franceschi E, Weller M, Chinot O, De Vos FYFL, et al: Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the Phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. Eur J Cancer. 147:1–12. 2021. View Article : Google Scholar : PubMed/NCBI

Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE, Marcello J, Herndon JE, Mathe A, Hamilton M, Rich JN, Norfleet JA, et al: Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 12:1300–1310. 2010. View Article : Google Scholar : PubMed/NCBI

Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, et al: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 353:2012–2024. 2005. View Article : Google Scholar : PubMed/NCBI

Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, et al: A Phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 12:87–94. 2010. View Article : Google Scholar : PubMed/NCBI

Lucas JT Jr, Knapp BJ, Uh J, Hua CH, Merchant TE, Hwang SN, Patay Z and Broniscer A: Posttreatment DSC-MRI is predictive of early treatment failure in children with supratentorial high-grade glioma treated with erlotinib. Clin Neuroradiol. 28:393–400. 2018. View Article : Google Scholar : PubMed/NCBI

Prados MD, Chang SM, Butowski N, DeBoer R, Parvataneni R, Carliner H, Kabuubi P, Ayers-Ringler J, Rabbitt J, Page M, et al: Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol. 27:579–54. 2009. View Article : Google Scholar : PubMed/NCBI

Hegi ME, Diserens AC, Bady P, Kamoshima Y, Kouwenhoven MCM, Delorenzi M, Lambiv WL, Hamou MF, Matter MS, Koch A, et al: Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib-a Phase II trial. Mol Cancer Ther. 10:1102–1112. 2011. View Article : Google Scholar : PubMed/NCBI

Wang Y, Liang D, Chen J, Chen H, Fan R, Gao Y, Gao Y, Tao R and Zhang H: Targeted therapy with anlotinib for a patient with an oncogenic FGFR3-TACC3 fusion and recurrent glioblastoma. Oncologist. 26:173–177. 2021. View Article : Google Scholar : PubMed/NCBI

Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, Clark BL and Lamar RE: Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer. 116:3663–3669. 2010. View Article : Google Scholar : PubMed/NCBI

Shahid S, Kushner BH, Modak S, Basu EM, Rubin EM, Gundem G, Papaemmanuil E and Roberts SS: Association of BRAF V600E mutations with vasoactive intestinal peptide syndrome in MYCN-amplified neuroblastoma. Pediatr Blood Cancer. 68:e292652021. View Article : Google Scholar : PubMed/NCBI

Rahman MA, Brekke J, Arnesen V, Hannisdal MH, Navarro AG, Waha A, Herfindal L, Rygh CB, Bratland E, Brandal P, et al: Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study. Immun Inflamm Dis. 8:342–359. 2020. View Article : Google Scholar : PubMed/NCBI

Morin A, Soane C, Pierce A, Sanford B, Jones KL, Crespo M, Zahedi S, Vibhakar R and Mulcahy Levy JM: Proteasome inhibition as a therapeutic approach in atypical teratoid/rhabdoid tumors. Neurooncol Adv. 2:vdaa0512020.PubMed/NCBI

Gupta SK, Kizilbash SH, Carlson BL, Mladek AC, Boakye-Agyeman F, Bakken KK, Pokorny JL, Schroeder MA, Decker PA, Cen L, et al: Delineation of MGMT hypermethylation as a biomarker for veliparib-mediated temozolomide-sensitizing therapy of glioblastoma. J Natl Cancer Inst. 108:djv3692016. View Article : Google Scholar : PubMed/NCBI

Xiong Y, Guo Y, Liu Y, Wang H, Gong W, Liu Y, Wang X, Gao Y, Yu F, Su D, et al: Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor. Neoplasia. 22:431–440. 2020. View Article : Google Scholar : PubMed/NCBI

Lowery MA, Burris HA III, Janku F, Shroff RT, Cleary JM, Azad NS, Goyal L, Maher EA, Gore L, Hollebecque A, et al: Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: A phase 1 study. Lancet Gastroenterol Hepatol. 4:711–720. 2019. View Article : Google Scholar : PubMed/NCBI

DiNardo CD, Hochhaus A, Frattini MG, Yee K, Zander T, Krämer A, Chen X, Ji Y, Parikh N, Choi J and Wei AH: A phase 1 study of IDH305 in patients with IDH1R132-mutant acute myeloid leukemia or myelodysplastic syndrome. J Cancer Res Clin Oncol. Mar 30–2022.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI

Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, et al: Randomized Phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro Oncol. 17:266–273. 2015. View Article : Google Scholar : PubMed/NCBI

Kesari S, Schiff D, Henson JW, Muzikansky A, Gigas DC, Doherty L, Batchelor TT, Longtine JA, Ligon KL, Weaver S, et al: Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro Oncol. 10:300–308. 2008. View Article : Google Scholar : PubMed/NCBI

Halatsch ME, Dwucet A, Schmidt CJ, Mühlnickel J, Heiland T, Zeiler K, Siegelin MD, Kast RE and Karpel-Massler G: In vitro and clinical compassionate use experiences with the drug-repurposing approach CUSP9v3 in glioblastoma. Pharmaceuticals (Basel). 14:12412021. View Article : Google Scholar : PubMed/NCBI

Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, et al: Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 23:1043–1053. 2012. View Article : Google Scholar : PubMed/NCBI

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, et al: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 16:1422018. View Article : Google Scholar : PubMed/NCBI

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, et al: Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol. 18:1373–1385. 2017. View Article : Google Scholar : PubMed/NCBI

Reardon DA, Desjardins A, Vredenburgh JJ, O'Rourke DM, Tran DD, Fink KL, Nabors LB, Li G, Bota DA, Lukas RV, et al: Rindopepimut with bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized Phase II trial. Clin Cancer Res. 26:1586–1594. 2020. View Article : Google Scholar : PubMed/NCBI